[{"id":"c0cd590d-13ce-4ae0-8ee5-2117a8d7e3c4","acronym":"NCI-2018-02016","url":"https://clinicaltrials.gov/study/NCT03698552","created_at":"2021-01-18T18:07:38.337Z","updated_at":"2024-07-02T16:35:03.675Z","phase":"Phase 1/2","brief_title":"ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT03698552 - NCI-2018-02016","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD22","pipe":" | ","alterations":" CD22 expression","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e epratuzumab-cys-tesirine (ADCT-602)"],"overall_status":"Recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 08/24/2018","start_date":" 08/24/2018","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-05-15"}]